References

Berruex F, Gerber V, Wohlfender FD, Burger D, Koch C. Clinical course of sarcoids in 61 Franches-Montagnes horses over a 5–7 year period. Vet Q. 2016; 36:(4)189-196 https://doi.org/10.1080/01652176.2016.1204483

Bradley WM, Schilpp D, Khatibzadeh SM. Electronic brachytherapy used for the successful treatment of three different types of equine tumours. Equine Vet Educ. 2017; 29:(6)293-298 https://doi.org/10.1111/eve.12420

Caston SS, Sponseller BA, Dembek KA, Hostetter JM. Evaluation of Locally Injected Mycobacterium Cell Wall Fraction in Horses with Sarcoids. J Equine Vet Sci. 2020; 90 https://doi.org/10.1016/j.jevs.2020.103102

Christen-Clottu O, Klocke P, Burger D, Straub R, Gerber V. Treatment of clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album austriacus). J Vet Intern Med. 2010; 24:(6)1483-1489 https://doi.org/10.1111/j.1939-1676.2010.0597.x

Compston PC, Turner T, Wylie CE, Payne RJ. Laser surgery as a treatment for histologically confirmed sarcoids in the horse. Equine Vet J. 2016; 48:(4)451-456 https://doi.org/10.1111/evj.12456

De Ridder T, Ruppin M, Wheeless M, Williams S, Reddell P. Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses. Front Vet Sci. 2020; 7 https://doi.org/10.3389/fvets.2020.00639

Echelmeyer J, Peckary R, Delarocque J, Patzl M, Feige K, Cavalleri J-MV. Effect of vaccination with human tyrosinase DNA in horses with melanoma in comparison with untreated horses. J Vet Intern Med. 2020; 35:(1) https://doi.org/10.1111/jvim.15994

Haspeslagh M, Vlaminck LEM, Martens AM. Treatment of sarcoids in equids: 230 cases (2008–2013). J Am Vet Med Assoc. 2016; 249:(3)311-318 https://doi.org/10.2460/javma.249.3.311

Haspeslagh M, Jordana Garcia M, Vlaminck LEM, Martens AM. Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study. BMC Vet Res. 2017; 13:(1) https://doi.org/10.1186/s12917-017-1215-0

Henson FMD, Dobson JM. Use of radiation therapy in the treatment of equine neoplasia. Equine Vet Educ. 2004; 16:(6)315-318 https://doi.org/10.1111/j.2042-3292.2004.tb00319.x

Hollis AR. Strontium-90 plesiotherapy in the horse. Equine Vet Educ. 2017; 31:(3)134-136 https://doi.org/10.1111/eve.12802

Hollis AR. Strontium plesiotherapy for the treatment of sarcoids in the horse. Equine Vet Educ. 2020; 32:(S11)7-11 https://doi.org/10.1111/eve.13038

Hollis AR, Berlato D. Initial experience with High Dose Rate Brachytherapy of periorbital sarcoids in the horse. Equine Vet Educ. 2017; 30:(8)444-449 https://doi.org/10.1111/eve.12782

Ireland JL, Wylie CE, Collins SN, Verheyen KLP, Newton JR. Preventive health care and owner-reported disease prevalence of horses and ponies in Great Britain. Res Vet Sci. 2013; 95:(2)418-424 https://doi.org/10.1016/j.rvsc.2013.05.007

Knottenbelt DC, Kelly DF. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999. Vet Ophthalmol. 2000; 3:(2-3)169-191 https://doi.org/10.1046/j.1463-5224.2000.00119.x

Knottenbelt DC, Watson AH, Hotchkiss JW, Chopra S, Higgins AJ. A pilot study on the use of ultra-deformable liposomes containing bleomycin in the treatment of equine sarcoid. Equine Vet Educ. 2020; 32:(5)258-263 https://doi.org/10.1111/eve.12950

Martens A, De Moor A, Vlaminck L, Pile F, Steenhaut M. Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids. Vet Rec. 2001; 149:(22)665-669 https://doi.org/10.1136/vr.149.22.665

Pettersson CM, Broström H, Humblot P, Bergvall KE. Topical treatment of equine sarcoids with imiquimod 5% cream or Sanguinaria canadensis and zinc chloride – an open prospective study. Vet Dermatol. 2020; 31:(6)471-e126 https://doi.org/10.1111/vde.12900

Phillips JC, Lembcke LM, Noltenius CE, Newman SJ, Blackford JT, Grosenbaugh DA, Leard AT. Evaluation of tyrosinase expression in canine and equine melanocytic tumors. Am J Vet Res. 2012; 73:(2)272-278 https://doi.org/10.2460/ajvr.73.2.272

Rols MP, Tamzali Y, Teissié J. Electrochemotherapy of horses. A preliminary clinical report. Bioelectrochemistry. 2002; 55:(1-2)101-105 https://doi.org/10.1016/S1567-5394(01)00156-6

Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S. Successful treatment of equine sarcoids by topical aciclovir application. Vet Rec. 2011; 168:(7) https://doi.org/10.1136/vr.c5430

Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: A retrospective study of 48 cases. Equine Vet J. 2012; 44:(2)214-220 https://doi.org/10.1111/j.2042-3306.2011.00425.x

Tozon N, Kramaric P, Kos Kadunc V, Sersa G, Cemazar M. Electrochemotherapy as a single treatment or adjuvant treatment to surgery of cutaneous sarcoid tumours in horses: a 31-case retrospective study. Vet Rec. 2016; 179:(24) https://doi.org/10.1136/vr.103867

An update on the treatment of cutaneous tumours

02 November 2021
9 mins read
Volume 5 · Issue 6
Figure 3. a. Fibroblastic and coalescing nodular sarcoid lesions on the face of a young horse. b. The same lesions, 24 hours after intra-lesional injection with tigilanol tiglate, showing the rapid development of haemorrhagic necrosis associated with the treatment
Figure 3. a. Fibroblastic and coalescing nodular sarcoid lesions on the face of a young horse. b. The same lesions, 24 hours after intra-lesional injection with tigilanol tiglate, showing the rapid development of haemorrhagic necrosis associated with the treatment

Abstract

Cutaneous tumours continue to present a significant clinical challenge in equine practice. There are a large number of treatment options and selecting the appropriate modality requires careful consideration of a number of factors. While sarcoids are the most commonly diagnosed cutaneous tumour, their clinical appearance can have considerable overlap with other types of lesion, so biopsy should be performed where the diagnosis is uncertain. New treatment options for sarcoids include electrosurgery, electrochemotherapy and novel intralesional treatments. Melanomas still have relatively limited treatment options beyond surgical resection, but there are now limited data to support the use of a xenogenic DNA vaccination protocol. Squamous cell carcinomas are generally best treated via surgical excision, but a novel intralesional treatment may prove to be a useful option for further treatment.

Sarcoids are the most common equine cutaneous tumour and continue to provide a clinical challenge. The majority of sarcoids are diagnosed based on their characteristic clinical appearance and locations, which is probably appropriate in most cases. Common locations for sarcoid lesions include the periocular region, axilla, inguinum and sheath, although they can occur anywhere, especially following a wound. However, it is important to recognise that other tumour types exist and can imitate sarcoids, especially nodular lesions. Where single nodular lesions are present and where lesions are in atypical locations, biopsy is strongly recommended to enable accurate diagnosis and appropriate treatment selection.

Benign neglect is most commonly employed with small occult or verrucose lesions. However, benign neglect may be a misnomer, as withholding treatment is not always a benign procedure. In a series of 42 periocular lesions that were not treated at the time of examination by a veterinary surgeon, all required treatment at a later stage and 64% of the horses were euthanised because the lesions were too extensive to treat at the time of referral (Knottenbelt and Kelly, 2000). However, in a series of 31 horses where some (but not all) of their sarcoid lesions were treated, some (but not all) of the untreated lesions spontaneously resolved regardless of the treatment used (Martens et al, 2001). Interestingly, in the same study, new lesions developed in 6 of the horses during the same time period (Martens et al, 2001). In a longitudinal study of 61 Franches-Montagnes horses, 38 horses had sarcoids documented at 3 years of age, but spontaneous regression occurred without any treatment in 65% of occult lesions and 32% of verrucose lesions (Berreux et al, 2016). It is not known if the same could be applied to other breeds, but the high prevalence of sarcoids in the Berreux et al (2016) study is surprising compared to the known owner-reported prevalence of 5.8% (Ireland et al, 2013). Although it is conceivable that many lesions are missed by owners, it is difficult to explain such a big discrepancy and to draw definitive conclusions. In one small placebo-controlled study, a complete or partial regression rate of 14% was reported in the placebo arm (Christen-Clottu et al, 2010), and in another study, 1.9% of small lesions spontaneously regressed (Pettersson et al, 2020), supporting the theory that some lesions may regress without specific therapy, albeit at a far smaller frequency than those reported in the Berreux et al (2016) study. Based on these data, benign neglect may be viable in a small number of early, small, occult or verrucose lesions, but regular monitoring is essential to ensure that lesions are not allowed to progress to the stage of being difficult to treat.

Register now to continue reading

Thank you for visiting UK-VET Equine and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.